These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21593572)

  • 21. Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.
    Pettigrew C; Soldan A; Moghekar A; Wang MC; Gross AL; O'Brien R; Albert M
    Neuropsychologia; 2015 Nov; 78():63-72. PubMed ID: 26394023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.
    Eckerström C; Olsson E; Bjerke M; Malmgren H; Edman A; Wallin A; Nordlund A
    J Alzheimers Dis; 2013; 36(3):421-31. PubMed ID: 23635408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minor neuropsychological deficits in patients with subjective cognitive decline.
    Wolfsgruber S; Kleineidam L; Guski J; Polcher A; Frommann I; Roeske S; Spruth EJ; Franke C; Priller J; Kilimann I; Teipel S; Buerger K; Janowitz D; Laske C; Buchmann M; Peters O; Menne F; Fuentes Casan M; Wiltfang J; Bartels C; Düzel E; Metzger C; Glanz W; Thelen M; Spottke A; Ramirez A; Kofler B; Fließbach K; Schneider A; Heneka MT; Brosseron F; Meiberth D; Jessen F; Wagner M;
    Neurology; 2020 Sep; 95(9):e1134-e1143. PubMed ID: 32636322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
    Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
    Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes.
    Hooshmand B; Lökk J; Solomon A; Mangialasche F; Miralbell J; Spulber G; Annerbo S; Andreasen N; Winblad B; Cedazo-Minguez A; Wahlund LO; Kivipelto M
    J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1132-8. PubMed ID: 24568931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden.
    Rolstad S; Berg AI; Eckerström C; Johansson B; Wallin A
    J Alzheimers Dis; 2015; 45(3):873-81. PubMed ID: 25633679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.
    Lerche S; Schulte C; Srulijes K; Pilotto A; Rattay TW; Hauser AK; Stransky E; Deuschle C; Csoti I; Lachmann I; Zetterberg H; Liepelt-Scarfone I; Gasser T; Maetzler W; Berg D; Brockmann K
    Mov Disord; 2017 Dec; 32(12):1780-1783. PubMed ID: 29094781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.
    Mattsson N; Portelius E; Rolstad S; Gustavsson M; Andreasson U; Stridsberg M; Wallin A; Blennow K; Zetterberg H
    J Alzheimers Dis; 2012; 30(4):767-78. PubMed ID: 22475796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between EEG abnormalities and CSF biomarkers in a memory clinic cohort.
    Kramberger MG; Kåreholt I; Andersson T; Winblad B; Eriksdotter M; Jelic V
    Dement Geriatr Cogn Disord; 2013; 36(5-6):319-28. PubMed ID: 24022277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
    Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
    Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M
    Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
    Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
    J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.